266 related articles for article (PubMed ID: 30545831)
21. Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin.
Mutch NJ; Engel R; Uitte de Willige S; Philippou H; Ariëns RA
Blood; 2010 May; 115(19):3980-8. PubMed ID: 20228273
[TBL] [Abstract][Full Text] [Related]
22. The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease.
Neergaard-Petersen S; Hvas AM; Kristensen SD; Grove EL; Larsen SB; Phoenix F; Kurdee Z; Grant PJ; Ajjan RA
Thromb Haemost; 2014 Dec; 112(6):1142-50. PubMed ID: 25187394
[TBL] [Abstract][Full Text] [Related]
23. Impaired fibrinolysis and increased clot strength are potential risk factors for thrombosis in lymphoma.
Bønløkke ST; Fenger-Eriksen C; Ommen HB; Hvas AM
Blood Adv; 2023 Nov; 7(22):7056-7066. PubMed ID: 37756519
[TBL] [Abstract][Full Text] [Related]
24. In vitro fibrin clot formation and fibrinolysis using heterozygous plasma fibrinogen from gammaAsn319, Asp320 deletion dysfibrinogen, Otsu I.
Terasawa F; Kani S; Hongo M; Okumura N
Thromb Res; 2006; 118(5):651-61. PubMed ID: 16412498
[TBL] [Abstract][Full Text] [Related]
25. Enhanced fibrinolysis by proteolysed coagulation factor Xa.
Talbot K; Meixner SC; Pryzdial EL
Biochim Biophys Acta; 2010 Apr; 1804(4):723-30. PubMed ID: 19931652
[TBL] [Abstract][Full Text] [Related]
26. Does Tranexamic Acid Improve Clot Strength in Severely Injured Patients Who Have Elevated Fibrin Degradation Products and Low Fibrinolytic Activity, Measured by Thrombelastography?
Moore HB; Moore EE; Chapman MP; Hansen KC; Cohen MJ; Pieracci FM; Chandler J; Sauaia A
J Am Coll Surg; 2019 Jul; 229(1):92-101. PubMed ID: 30936005
[TBL] [Abstract][Full Text] [Related]
27. Plasma-based assays distinguish hyperfibrinolysis and shutdown subgroups in trauma-induced coagulopathy.
Lawson MA; Holle LA; Dow NE; Hennig G; de Laat B; Moore HB; Moore EE; Cohen MJ; Bouchard BA; Freeman K; Wolberg AS
J Trauma Acute Care Surg; 2022 Nov; 93(5):579-587. PubMed ID: 35687811
[TBL] [Abstract][Full Text] [Related]
28. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
Konieczynska M; Fil K; Bazanek M; Undas A
Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
[TBL] [Abstract][Full Text] [Related]
29. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
Gurewich V; Pannell R
Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
[TBL] [Abstract][Full Text] [Related]
30. Molecular mechanisms of initiation of fibrinolysis by fibrin.
Medved L; Nieuwenhuizen W
Thromb Haemost; 2003 Mar; 89(3):409-19. PubMed ID: 12624622
[TBL] [Abstract][Full Text] [Related]
31. Resistance of gammaA/gamma' fibrin clots to fibrinolysis.
Falls LA; Farrell DH
J Biol Chem; 1997 May; 272(22):14251-6. PubMed ID: 9162058
[TBL] [Abstract][Full Text] [Related]
32. The role of activated coagulation factor XII in overall clot stability and fibrinolysis.
Konings J; Hoving LR; Ariëns RS; Hethershaw EL; Ninivaggi M; Hardy LJ; de Laat B; Ten Cate H; Philippou H; Govers-Riemslag JW
Thromb Res; 2015 Aug; 136(2):474-80. PubMed ID: 26153047
[TBL] [Abstract][Full Text] [Related]
33. Fibrinolysis in trauma patients: wide variability demonstrated by the Lysis Timer.
Roullet S; Weinmann L; Labrouche S; Gisbert-Mora C; Biais M; Revel P; Freyburger G
Scand J Clin Lab Invest; 2019; 79(1-2):136-142. PubMed ID: 30861350
[TBL] [Abstract][Full Text] [Related]
34. Differential effects of staphylokinase, streptokinase and tissue-type plasminogen activator on the lysis of retracted human plasma clots and fibrinolytic plasma parameters in vitro.
Hauptmann J; Glusa E
Blood Coagul Fibrinolysis; 1995 Sep; 6(6):579-83. PubMed ID: 7578902
[TBL] [Abstract][Full Text] [Related]
35. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
Nielsen VG
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):584-7. PubMed ID: 20683324
[TBL] [Abstract][Full Text] [Related]
36. Interpretation and Validation of Maximum Absorbance Data Obtained from Turbidimetry Analysis of Plasma Clots.
Pieters M; Guthold M; Nunes CM; de Lange Z
Thromb Haemost; 2020 Jan; 120(1):44-54. PubMed ID: 31752041
[TBL] [Abstract][Full Text] [Related]
37. Myosin: a noncovalent stabilizer of fibrin in the process of clot dissolution.
Kolev K; Tenekedjiev K; Ajtai K; Kovalszky I; Gombas J; Váradi B; Machovich R
Blood; 2003 Jun; 101(11):4380-6. PubMed ID: 12543859
[TBL] [Abstract][Full Text] [Related]
38. Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis.
Liu JN; Liu JX; Liu Bf BF; Sun Z; Zuo JL; Zhang Px PX; Zhang J; Chen Yh YH; Gurewich V
Circ Res; 2002 Apr; 90(7):757-63. PubMed ID: 11964367
[TBL] [Abstract][Full Text] [Related]
39. Tranexamic acid mediates proinflammatory and anti-inflammatory signaling via complement C5a regulation in a plasminogen activator-dependent manner.
Barrett CD; Moore HB; Kong YW; Chapman MP; Sriram G; Lim D; Moore EE; Yaffe MB
J Trauma Acute Care Surg; 2019 Jan; 86(1):101-107. PubMed ID: 30575685
[TBL] [Abstract][Full Text] [Related]
40. Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy.
Sakharov DV; Nagelkerke JF; Rijken DC
J Biol Chem; 1996 Jan; 271(4):2133-8. PubMed ID: 8567670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
